Sema4, a Disruptive AI-driven Genomic & Clinical Data Platform Company, to Combine with CM Life Sciences to Accelerate Growth Transaction combines Sema4's leading AI- and machine learning-powered integrated genomic and c

a Disruptive AI-driven Genomic & Clinical Data Platform Company, to Combine with CM Life Sciences to Accelerate Growth

YORK, NY & STAMFORD, CT - February 10, 2021 - Sema4, an AI- and machine learning- driven patient-centered

genomic and clinical data intelligence company, and CM Life Sciences (Nasdaq: CMLF), a special purpose acquisition company, or

SPAC, sponsored by affiliates of Casdin Capital, LLC and Corvex Management LP, today announced they have entered into a definitive

business combination agreement. Upon closing of the transaction, CM Life Sciences will be renamed and its common stock will be

listed on the Nasdaq Global Market under a name and a ticker symbol to be announced at a later date.

transaction is a significant milestone for Sema4," said Eric Schadt, Ph.D., Founder and CEO of Sema4. "The additional

resources will allow us to greatly accelerate our business plans organically and inorganically, developing and bringing in more

cutting-edge precision model solutions across multiple disease areas. This is the most exciting time in the history of our industry

and I look forward to working closely with Eli, Keith, and their teams, to deliver on the massive potential to transform clinical

and life sciences through better leveraging of data."

a purpose built and rapidly growing, patient-centered genomic and clinical data insight platform company. Leveraging world leading

data scientists using artificial intelligence and machine learning, the company is powering remarkable and unique insights that

transform the practice of medicine and how disease is diagnosed, treated, and prevented.

today has established the largest, most comprehensive, and fastest growing integrated genomic & clinical data platform. Sema4

has established its platform in partnership with patients, healthcare providers and a far-reaching ecosystem of life science industry

database includes more than 10 million patient genomic profiles and de-identified clinical records, integrated and delivered in

a way that enables physicians to proactively diagnose and manage disease. The virtuous cycle of data helps improve decision making

but also accelerates the development of next generation diagnostic tools and therapeutics.

exist in a remarkable period of time as the life sciences and broad healthcare industries undergo a technology-driven data revolution,"

said Eli Casdin, founder and CIO of Casdin Capital. "The disruptive promise in combining these genomic and clinical data

sets, at the patient level, is profound but takes a team of experts, the right business model, and lots of growth capital. We

therefore could not be more excited to lend our partnership and fill the balance sheet for the foremost leader in the field, Eric

Schadt and the expert team he's assembled at Sema4. With an early start, unique business strategy and more than 150 leading

data scientists, this is the premier company in one of the biggest, winner-take-most markets in life sciences."

addition to the approximately $443 million of cash held in CM Life Sciences' trust account, a group of leading institutional

investors has committed to participate in the transaction through a common stock PIPE of $350 million including funds advised

by Casdin Capital and Corvex Management, new investors Fidelity Management & Research Company LLC, Counterpoint Global (Morgan

Stanley), Perceptive Advisors, SB Management, a subsidiary of SoftBank Group Corp, funds and accounts advised by T. Rowe Price

Associates Inc and Viking Global Investors, and existing investors including funds and accounts managed by Blackrock and Deerfield

Management, among other top-tier healthcare investors.

combined company is expected to receive proceeds of up to approximately $793 million at the closing of the transaction, up to

$343 million of which will be paid to Sema4 stockholders and the remainder of which will be utilized by Sema4 in its business

and will continue to operate under the Sema4 management team, led by Eric Schadt, Ph.D., Founder and CEO. The transaction, which

values Sema4 at an enterprise value of approximately $2 billion, is expected to close during the second quarter of 2021, and will

provide Sema4 with significant additional capital to further build and scale upon its dedication to advancing healthcare through

data-driven insights.

will be used to both fuel organic operating needs and to drive other targeted growth opportunities, helping the company deliver

its solutions to a larger number of healthcare providers and patients and to improve clinical outcomes across a higher volume

has built a truly unique business at Sema4 with a combination of scale, growth and innovation that we rarely see. Revenues are

projected to grow from $200 million to $500 million and gross margins to double from today to 2023, while Sema4 leverages its

existing platform in women's health and oncology to quickly grow into high margin relationships and partnerships across

health systems and biopharma partners," said Keith Meister, Chairman of the Board CM Life Sciences. "This transaction

affords investors the unique opportunity to benefit from Sema4's rapid growth, business transformation and the multiple

expansion opportunities that we believe this growth will drive."

February 9, 2021, CM Life Sciences entered into a definitive agreement to combine with Sema4. The transaction is expected to deliver

up to $793 million of gross proceeds, including the contribution of up to $443 million of cash held in CM Life Sciences'

trust account from its initial public offering in September 2020 (assuming no redemptions from the trust account) and $350 million

from committed equity PIPE funding from a group of institutional and life sciences investors. In the transaction, Sema4 shareholders

will receive common stock of CM Life Sciences and, at their election, up to $343 million in cash in exchange for shares of Sema4.

Upon completion of the transaction, Sema4 expects to have up to $500 million in cash available from the transaction ($450

million from the transaction plus existing cash on its balance sheet at closing) to fund operations and support new and existing

business initiatives.

transaction has been unanimously approved by each of CM Life Sciences' and Sema4's Board of Directors and substantially

all of the shareholders of Sema4. The transaction is subject to the approval of the CM Life Sciences shareholders and other customary

conditions, and is expected to close in the second quarter.

information about the proposed transaction, including a copy of the Merger Agreement and an investor presentation, will be provided

in a Current Report on Form 8-K to be filed today with the Securities and Exchange Commission ("SEC") and available

LLC is acting as sole financial advisor, lead capital markets advisor, and sole placement agent, with Cowen and Company, LLC

also acting as a capital markets advisor, and White & Case LLP is serving as legal advisor to CM Life Sciences. Goldman Sachs

& Co. LLC and J.P. Morgan Securities LLC are serving as financial advisors, and Fenwick & West LLP is serving as legal

webcast of the conference call and associated presentation materials is available on Deal Roadshow:

Roadshow Investor Login Details

Link: https://dealroadshow.com/e/CM226

Life Sciences was founded to take advantage of a dynamic life science sector buoyed by innovation yet fragmented, where many companies

are under-resourced and under-scaled. Significant and under-appreciated opportunities for consolidation are ready for engagement

by a team versed in the trends and themes, and who can bring together the strongest of the new companies and management teams

to capitalize on near- and far-term opportunities. For more information, please visit: https://cmlifesciencesspac.com/

is an AI-driven patient-centered genomic and clinical data insight platform company founded on the idea that more information,

deeper analysis, and increased engagement will improve the diagnosis, treatment, and prevention of disease. Sema4 is dedicated

to transforming healthcare by building dynamic models of human health and defining optimal, individualized health trajectories,

starting in the areas of reproductive health and oncology. Centrellis , our innovative health intelligence platform,

is enabling us to generate a more complete understanding of disease and wellness and to provide science-driven solutions

to the most pressing medical needs. Sema4 believes that patients should be treated as partners, and that data should be shared

for the benefit of all.

more information, please visit sema4.com and connect with Sema4 on Twitter, LinkedIn, Facebook and YouTube.

Statement Regarding Forward Looking Statements

press release contains certain forward-looking statements within the meaning of the federal securities laws with respect to the

proposed transaction between Sema4 and CM Life Sciences, including statements regarding the anticipated benefits of the transaction,

the anticipated timing of the transaction, expansion plans, projected future results and market opportunities of Sema4. These

forward-looking statements generally are identified by the words "believe," "project," "expect,"

"anticipate," "estimate," "intend," "strategy," "future," "opportunity,"

"plan," "may," "should," "will," "would," "will be," "will

continue," "will likely result," and similar expressions. Forward-looking statements are predictions, projections

and other statements about future events that are based on current expectations and assumptions and, as a result, are subject

to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements

in this press release, including but not limited to: (i) the risk that the transaction may not be completed in a timely manner

or at all, which may adversely affect the price of CM Life Sciences' securities, (ii) the risk that the transaction may

not be completed by CM Life Sciences' business combination deadline and the potential failure to obtain an extension of

the business combination deadline if sought by CM Life Sciences, (iii) the failure to satisfy the conditions to the consummation

of the transaction, including the adoption of the merger agreement by the shareholders of CM Life Sciences, the satisfaction of

the minimum trust account amount following redemptions by CM Life Sciences' public shareholders and the receipt of certain

governmental and regulatory approvals, (iv) the lack of a third-party valuation in determining whether or not to pursue the transaction,

(v) the inability to complete the PIPE investment in connection with the transaction, (vi) the occurrence of any event, change

or other circumstance that could give rise to the termination of the merger agreement, (vii) the effect of the announcement or

pendency of the transaction on Sema4's business relationships, operating results and business generally, (viii) risks that

the proposed transaction disrupts current plans and operations of Sema4 and potential difficulties in Sema4 employee retention

as a result of the transaction, (ix) the outcome of any legal proceedings that may be instituted against Sema4 or against CM Life